series-a
Stage
2018
Founded
1
Investors
About
Triumvira Immunologics develops T-Cell Antigen Coupler (TAC) therapeutics — autologous and allogeneic cell therapies designed to treat solid tumors and blood cancers with an improved safety profile versus conventional CAR‑T approaches. In March 2021 the company submitted an IND to the FDA and began enrolling patients in a Phase I trial in collaboration with MD Anderson Cancer Center.
Explore Triumvira Immunologics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.